Position summary
The Area Business Director will lead a team of firstline leaders (Regional Business Directors) in the East, who in turn lead a team of sales representatives (Rare Disease Account Managers). The individual will report to the VP, Sales (Tarpeyo).
In this role, you will develop the area business strategy, and hire and lead a team of high performing first line leaders to achieveexceed business and sales goals. You will work closely with the VP Sales (Tarpeyo), your peers and other Senior Leaders across the organization to develop and execute strategies and initiatives that contribute to the overall performance, culture and success of the organization.
As needed, the Area Business Director will participate in field based activities, including but not limited to representing sales leadership at individual and group sales presentations to targeted healthcare professionals, analysis of performance data and market trends in order to identify business opportunities, creating comprehensive and detailed business plans for execution at launch and collaborating with various Headquarterbased colleaguesstakeholders to develop materials and customerfocused initiatives targeted for a diverse range of healthcare professionals. The Area Business Director must have a playercoach mentality with a willingness to own highvalue account relationships.
Key tasks and responsibilities
Education and experience requirements
Reasons to join the Calliditas Team
Welcome to join the Calliditas Team!
About Calliditas Therapeutics
Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas’ lead product, developed under the name Nefecon, has received full approval by the FDA under the trade name TARPEYO® and by the European Commission under the trade name KINPEYGO®. TARPEYOKINPEYGO® is the first treatment approved for IgA nephropathy by the FDA and EMA, respectively.
Calliditas also has a pipeline to address a variety of diseases, including primary biliary cholangitis (PBC), idiopathic pulmonary fibrosis (IPF), Alport Syndrome and solid tumors (SCCHN).
In 2024, Calliditas Therapeutics was acquired by Asahi Kasei.
Calliditas is an EVerify employer.
#LIDNI
Boomering Inc
AireSpring
Cribl
Nidec Motor Corporation
Fotona Lasers US